News + Resources
Keep up with the latest
Featured
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
CRISPR 2.0, the Next Generation
June 21, 2024
Aspen Ideas: Health
CRISPR 2.0, the Next Generation
June 21, 2024
All Stories
News
Growing East Bay biotech Scribe Therapeutics lines up potential $1.5 billion CRISPR deal
May 16, 2023
San Francisco Business Times
Read Now
Press Release
Growing East Bay biotech Scribe Therapeutics lines up potential $1.5 billion CRISPR deal
May 16, 2023
San Francisco Business Times
Read Now
News
Scribe Therapeutics Announces Oral Presentation at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 2, 2023
Read Now
Press Release
Scribe Therapeutics Announces Oral Presentation at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 2, 2023
Read Now
News
The New Age of CRISPR
April 11, 2023
Biotechnology Innovation Organization
Read Now
Press Release
The New Age of CRISPR
April 11, 2023
Biotechnology Innovation Organization
Read Now
News
Scribe Therapeutics to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days
March 31, 2023
Read Now
Press Release
Scribe Therapeutics to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days
March 31, 2023
Read Now